Page last updated: 2024-12-08

potassium bromide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

potassium bromide : A metal bromide salt with a K(+) counterion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID253877
CHEMBL ID1644030
CHEBI ID32030
MeSH IDM0117052

Synonyms (102)

Synonym
KBR ,
kaliumbromid
CHEBI:32030 ,
epa pesticide chemical code 013903
hsdb 5044
ccris 6095
einecs 231-830-3
potassium bromide [jan]
nsc 77367
bromure de potassium
caswell no. 684
potassium bromide (k3br3)
tripotassium tribromide
kalii bromidum
nsc-77367
nsc77367
bromide salt of potassium
potassium bromide (kbr)
potassium bromide
7758-02-3
potassium bromide, bioxtra, >=99.0%
potassium bromide, anhydrous, beads, -10 mesh, >=99.9% trace metals basis
potassium bromide, anhydrous, powder, 99.95% trace metals basis
potassium bromide, anhydrous, powder, 99.999% trace metals basis
D01731
potassium bromide (jp17/usp)
potassium bromide (tn)
potassium bromide, 99.99% trace metals basis
chembl1644030 ,
potassium bromide, bioultra, >=99.5% (at)
kali bromatum
ec 231-830-3
psorizide forte
psorizide ultra
osd78555zm ,
potassium bromide [usp:jan]
unii-osd78555zm
P1747
AKOS015950615
FT-0645099
potassium bromide [mart.]
kali bromatum [hpus]
potassium bromide [inci]
potassium bromide [ep monograph]
potassium bromide [usp monograph]
potassium bromide [hsdb]
potassium bromide [who-dd]
potassium bromide [mi]
BR1193
potassium bromide acs reagent
IOLCXVTUBQKXJR-UHFFFAOYSA-M
potassium bromide crystal optic rectangle, 30mm x 15mm x 4mm, polished both sides
potassium bromide crystal optic disc, 25mm x 2mm, polished both sides
potassium bromide crystal optic disc, 22mm x 4mm, polished both sides
potassium bromide crystal optic rectangle, 38.5mm x 19.5mm x 4mm, polished both sides
potassium bromide crystal optic disc, 13mm x 1mm, polished both sides
potassium bromide crystal optic rectangle, 41mm x 23mm x 6mm, polished both sides
potassium bromide crystal optic disc, 13mm x 2mm, unpolished
potassium bromide crystal optic disc, 25mm x 5mm, unpolished
potassium bromide crystal optic disc, 32mm x 3mm, polished both sides
potassium bromide crystal optic disc, 32mm x 3mm, unpolished
potassium bromide crystal optic disc, 38mm x 6mm, polished both sides
potassium bromide crystal optic disc, 32mm x 3mm (drilled), polished both sides
potassium bromide crystal optic disc, 25mm x 4mm, polished both sides
AKOS024437429
potassiumbromide
potassium bromide, bp, ph. eur. grade
DTXSID5025946 ,
mfcd00011358
potassium bromide, ftir grade
potassium bromide, ultra dry
potassium bromide, anhydrous, free-flowing, redi-dri(tm), acs reagent, >=99%
potassium bromide, anhydrous, free-flowing, redi-dri(tm), reagentplus(r), >=99%
potassium bromide, jis special grade, 99.0-100.2%
potassium bromide, saj first grade, 99.0-101.0%
potassium bromide, puriss., meets analytical specification of ph. eur., bp, usp, 99.5-100.5%
potassium bromide, acs reagent, >=99.0%
potassium bromide, puriss. p.a., acs reagent, >=99.5% (at)
potassium bromide, ft-ir grade, >=99% trace metals basis
potassium bromide, ar, >=99.5%
potassium bromide, reagentplus(r), >=99.0%
potassium bromide, lr, >=99%
potassium bromide, spectroscopy
potassium bromide, p.a., 99.0%
potassium bromide, usp, 98.0-100.5%
potassium bromide, vetec(tm) reagent grade, 99%
potassium bromide, trace metals grade 99.99%
BCP21085
Q2546
potassium;bromide
potassium bromide (usp:jan)
k-brovet 500
kbrovet-ca1 500
dtxcid905946
potassium bromide (mart.)
potassium bromide (ep monograph)
potassium bromide (usp monograph)
kbrovet-ca1
k-brovet 250
kbrovet-ca1 250
k-brovet
usepa/opp pesticide code: 013903

Research Excerpts

Overview

Potassium bromide is a readily available, affordable salt. It has a long history of medical use as an anxiolytic, sedative and antiseizure therapy.

ExcerptReferenceRelevance
"Potassium bromide is an old AED."( Epilepsy of infancy with migrating focal seizures: six patients treated with bromide.
Caraballo, R; Fortini, PS; Pasteris, MC; Portuondo, E, 2014
)
1.12
"Potassium bromide is a readily available, affordable salt with a long history of medical use as an anxiolytic, sedative and antiseizure therapy in other species."( Pharmacokinetics of bromide in adult sheep following oral and intravenous administration.
Combs, MD; Edwards, SH; Quast, TA,
)
0.85

Treatment

Potassium bromide treatment was lowered by 15 % without further dietary changes. Treatment induced a significant reduction in the rear engagements during the whole trial period (221 days)

ExcerptReferenceRelevance
"Potassium bromide treatment was lowered by 15 % without further dietary changes."( Bromide toxicosis (bromism) secondary to a decreased chloride intake after dietary transition in a dog with idiopathic epilepsy: a case report.
Debreuque, M; Fantinati, M; Priymenko, N, 2021
)
1.34
"The treatment with potassium bromide induced a significant reduction in the rear engagements during the whole trial period (221 days), in direct attacks during the period A (from day 0 to day 53) and in side-on attacks during the period B (from day 54 to day 167)."( [Effect of an oral sedative on the behavior and the zootechnologic performance of fattening bulls of the white-blue Belgian breed].
Genicot, B; Lekeux, P; Mouligneau, F, 1991
)
0.6

Toxicity

ExcerptReferenceRelevance
" Although adverse effects are not evident in animals fed bread-based diets made from flour treated with KBrO3, the agent is carcinogenic in rats and nephrotoxic in both man and experimental animals when given orally."( Toxicity and carcinogenicity of potassium bromate--a new renal carcinogen.
Hayashi, Y; Kurokawa, Y; Maekawa, A; Takahashi, M, 1990
)
0.28
" In rats fed the diets fumigated with methyl bromide there were no marked toxic changes, except for a slight depression of body-weight gain from wk 60 onwards in males of the 500-ppm group, and tumour incidence was unaffected."( Two-year oral chronic toxicity and carcinogenicity study in rats of diets fumigated with methyl bromide.
Kosaka, T; Maita, K; Mitsumori, K; Miyaoka, T; Shirasu, Y, 1990
)
0.28
" As hydrogen peroxide is a necessary factor for triggering a number of important toxic effects of nitrite, the latter increases its toxicity by inhibiting catalase."( Nitrite-catalase interaction as an important element of nitrite toxicity.
Petrenko, YM; Titov, VY, 2003
)
0.32
" Abrupt dietary changes or fluid therapy may compromise seizure control or increase the likelihood of adverse events."( A systematic review of the safety of potassium bromide in dogs.
Baird-Heinz, HE; Hungerford, LL; Pelsor, FR; Ranivand, L; Van Schoick, AL, 2012
)
0.65

Pharmacokinetics

ExcerptReferenceRelevance
" Median elimination half-life and steady-state serum concentration were 15."( Pharmacokinetics and toxicity of bromide following high-dose oral potassium bromide administration in healthy Beagles.
March, PA; Podell, M; Sams, RA, 2002
)
0.55
" Serum concentrations of KBr were measured to construct concentration versus time curves and to calculate pharmacokinetic parameters."( Pharmacokinetics of potassium bromide in adult horses.
Edwards, S; Raidal, SL, 2005
)
0.65
" Serum concentrations of bromide were determined by colorimetric spectrophotometry following drug administration to permit determination of concentration versus time curves from which pharmacokinetic parameters could be calculated."( Pharmacokinetics of potassium bromide in adult horses.
Edwards, S; Raidal, SL, 2008
)
0.67
" After PO administration the Cmax was 453."( Pharmacokinetics of bromide in adult sheep following oral and intravenous administration.
Combs, MD; Edwards, SH; Quast, TA,
)
0.13
"When administered PO, bromide in sheep has a long half-life (t½ ) of approximately 14 days, with good bioavailability."( Pharmacokinetics of bromide in adult sheep following oral and intravenous administration.
Combs, MD; Edwards, SH; Quast, TA,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
" When phenobarbital is used in combination with bromide, a reasonable therapeutic range for serum phenobarbital concentrations is 9 to 36 micrograms/ml, although in some dogs treated with bromide, phenobarbital can eventually be discontinued."( Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996).
Carrillo, J; Schwark, WS; Trepanier, LA; Van Schoick, A, 1998
)
0.53

Bioavailability

ExcerptReferenceRelevance
" The range of steady-state concentrations achieved suggests individual differences in clearance and bioavailability between dogs."( Pharmacokinetics and toxicity of bromide following high-dose oral potassium bromide administration in healthy Beagles.
March, PA; Podell, M; Sams, RA, 2002
)
0.55
" The oral bioavailability (F) of bromide was 92%."( Pharmacokinetics of bromide in adult sheep following oral and intravenous administration.
Combs, MD; Edwards, SH; Quast, TA,
)
0.13

Dosage Studied

Bromide toxicosis was diagnosed in an 8-year-old Labrador Retriever that had been treated for epilepsy with potassium bromide, at a dosage of 29 mg/kg of body weight/d. This case of bromism in a dog suggests that the dosage of potassium Bromide should be based on serial measurement of serum bromides.

ExcerptRelevanceReference
" This case of bromism in a dog suggests that the dosage of potassium bromide should be based on serial measurement of serum bromide concentrations."( Bromide toxicosis (bromism) in a dog treated with potassium bromide for refractory seizures.
Morrison, WB; Sharp, PE; Yohn, SE, 1992
)
0.78
" We report the glow curve and dose-response characteristics to 60Co gamma rays."( Dosimetric properties of europium-doped potassium bromide thermoluminescent crystals.
Brandan, ME; Buenfil, AE, 1992
)
0.55
" Serum concentrations differed even with the same dosage among individual dogs."( [Effectiveness of bromide in therapy resistant epilepsy of dogs].
Jürgens, U; Schwartz-Porsche, D, 1991
)
0.28
" It is concluded that water-soluble deliquescent substances, normally encountered in pharmaceutical dosage forms, rapidly form saturated aqueous solutions in the aqueous film formed as water vapor uptake proceeds, and that the water uptake rate can be predicted a priori from known and experimentally determinable parameters using the heat transport model."( Moisture sorption kinetics for water-soluble substances. IV: Studies with mixtures of solids.
Kontny, MJ; Zografi, G, 1985
)
0.27
" Of the 12 patients experiencing side effects, including drowsiness, appetite loss, and skin rash, 1 required a reduction in BR dosage because of an extensive acneiform rash on the face."( Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant.
Fukuyama, Y; Hara, M; Hayashi, K; Izumi, T; Mukahira, A; Oguni, H; Oguni, M; Uehara, T; Umezu, R,
)
0.13
"Bromide toxicosis was diagnosed in an 8-year-old Labrador Retriever that had been treated for epilepsy with potassium bromide, at a dosage of 29 mg/kg of body weight/d."( Bromide toxicosis secondary to renal insufficiency in an epileptic dog.
Linn, K; Nichols, ES; Trepanier, LA, 1996
)
0.51
" High chloride intake increases the elimination of bromide in dogs, leading to higher dosage requirements for bromide in dogs fed high-chloride diets."( High dietary chloride content associated with loss of therapeutic serum bromide concentrations in an epileptic dog.
Center, SA; Garland, S; Shaw, N; Trepanier, LA, 1996
)
0.29
" Individual optimal drug dosage can be calculated for each patient at little cost to the pet owner."( Drug choice and therapeutic drug monitoring in the management of canine primary epilepsy.
Taylor, JH; Vaughan-Scott, T, 1999
)
0.3
"To establish a dosing regimen for potassium bromide and evaluate use of bromide to treat spontaneous seizures in cats."( Disposition and clinical use of bromide in cats.
Boothe, DM; Couch, P; George, KL, 2002
)
0.59
" Dogs showed no neurologic deficits during maintenance dosing but significant latency shifts in waves I and V of the brainstem auditory evoked response were evident."( Pharmacokinetics and toxicity of bromide following high-dose oral potassium bromide administration in healthy Beagles.
March, PA; Podell, M; Sams, RA, 2002
)
0.55
"Three simple, accurate and sensitive colorimetric methods (A, B and C) for the determination of ranitidine HCl (RHCl) in bulk sample, in dosage forms and in the presence of its oxidative degradates are described."( Utility of oxidation-reduction reaction for the determination of ranitidine hydrochloride in pure form, in dosage forms and in the presence of its oxidative degradates.
Ahmed, IS; Amin, AS; Dessouki, HA; Gouda, EA, 2003
)
0.32
" Prolonged oral administration with twice-daily dosing of ELB 138 with either 5 or 40 mg/kg over a 5-week period was not associated with loss of anticonvulsant efficacy in the PTZ dog model."( Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures.
Löscher, W; Potschka, H; Rieck, S; Rundfeldt, C; Tipold, A, 2004
)
0.32
"Patients were stabilised using phenobarbitone and/or potassium bromide to produce tolerable therapeutic serum concentrations and dosed additionally with gabapentin at 35 to 50 mg/kg/d (divided twice or three times daily) for 4 months."( Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent.
Govendir, M; Malik, R; Perkins, M, 2005
)
0.58
" A significant relationship was found between body condition score and fasting serum triglyceride concentration in all dogs, but serum triglyceride concentration was not significantly associated with phenobarbital dosage or serum phenobarbital concentration."( Serum triglyceride concentration in dogs with epilepsy treated with phenobarbital or with phenobarbital and bromide.
Govendir, M; Ilkin, WJ; Kluger, EK; Malik, R; Snow, D; Sullivan, DR, 2008
)
0.35
"1 μg/ml) and potassium bromide (n=2; 30-36 mg/kg/d)) resulted in successful reduction of intravenous barbiturate dosage and withdrawal from artificial ventilation."( Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase.
Imamura, A; Maegaki, Y; Maruta, K; Matsunami, K; Narita, A; Nishimura, Y; Ohno, K; Saiki, Y; Saito, Y; Sokota, T; Sugihara, S; Tamasaki, A; Ueda, R, 2015
)
0.79
" Overall, suspensions were the most dispensed (47%), extemporaneously compounded dosage forms followed by solutions (28%), and capsules (10%)."( Evaluation of the Most Frequently Prescribed Extemporaneously Compounded Veterinary Medications at a Large Independent Community Pharmacy.
Demir, Z; Hines, R; Horsey, R; Karara, AH; Nnorom, B; Twigg, G,
)
0.13
" The method can be applied in the routine analysis of vancomycin dosage form and is an important option for the current and sustainable pharmaceutical analysis."( A New and Ecological Method to Quantify Vancomycin in Pharmaceutical Product by Infrared Spectrometry.
Kogawa, AC; Nascimento, PAD; Salgado, HRN, 2021
)
0.62
" Given a patient's pre- and during-treatment information, ARTE can estimate treatment outcomes for a selected daily dosage value (radiation fraction size)."( A clinical decision support system for AI-assisted decision-making in response-adaptive radiotherapy (ARCliDS).
Cuneo, K; Dinov, ID; El Naqa, I; Jamaluddin, J; Jin, J; Jolly, S; Lawrence, TS; Luo, Y; Matuszak, MM; Niraula, D; Sun, W; Ten Haken, RK, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
potassium saltAny alkali metal salt having potassium(1+) as the cation.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)Ki4,000.00000.00001.372610.0000AID552171
Carbonic anhydrase 2Homo sapiens (human)Ki63,000.00000.00000.72369.9200AID552172
Carbonic anhydrase 4Homo sapiens (human)Ki90.00000.00021.97209.9200AID552173
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki50,000.00000.00001.27259.9000AID552169
Carbonic anhydrase 9Homo sapiens (human)Ki16,000.00000.00010.78749.9000AID552168
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID552170Inhibition of Dicentrarchus labrax alpha-carbonic anhydrase by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
AID552171Inhibition of human carbonic anhydrase 1 by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
AID552173Inhibition of human carbonic anhydrase 4 by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
AID552172Inhibition of human carbonic anhydrase 2 by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
AID552169Inhibition of human carbonic anhydrase 5 by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
AID552168Inhibition of human carbonic anhydrase 9 by Lineweaver-Burk curves2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Characterization and anions inhibition studies of an α-carbonic anhydrase from the teleost fish Dicentrarchus labrax.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (308)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (13.64)18.7374
1990's53 (17.21)18.2507
2000's116 (37.66)29.6817
2010's80 (25.97)24.3611
2020's17 (5.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 84.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index84.59 (24.57)
Research Supply Index5.82 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index150.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (84.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (2.74%)5.53%
Reviews12 (3.66%)6.00%
Case Studies41 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other266 (81.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]